|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
CA2081368A1
(en)
|
1990-03-27 |
1991-09-28 |
Ian S. Trowbridge |
Method for inhibiting cell growth and compositions useful therefor
|
|
US5648469A
(en)
|
1992-04-20 |
1997-07-15 |
The Salk Institute For Biological Studies |
Monoclonal antibodies reactive with transferrin receptor cytoplasmic domain
|
|
WO2005094364A2
(en)
|
2004-03-31 |
2005-10-13 |
Chimeric Technologies, Inc. |
Iga antibody protein as a cytotoxic drug
|
|
CA2561830C
(en)
|
2004-03-31 |
2013-05-21 |
Adnagen Ag |
Monoclonal antibodies with specificity for fetal erythroid cells
|
|
WO2005111082A1
(en)
|
2004-04-30 |
2005-11-24 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-tfr antibody.
|
|
AU2005252699B2
(en)
|
2004-06-07 |
2010-12-23 |
Macrogenics West, Inc. |
Transferrin receptor antibodies
|
|
CZ200755A3
(cs)
|
2004-07-26 |
2007-04-11 |
Biogen Idec Ma Inc. |
Peptidy protilátek anti-CD154
|
|
JP2008531060A
(ja)
|
2005-03-04 |
2008-08-14 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
相補性決定残基の合理的改変を介して免疫グロブリン可変領域をヒト化する方法
|
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
FR2953841B1
(fr)
|
2009-12-16 |
2011-12-30 |
Centre Nat Rech Scient |
Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
|
|
FR2959416B1
(fr)
|
2010-05-03 |
2012-06-22 |
Monoclonal Antibodies Therapeutics Mat Biopharma |
Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
|
|
WO2012075037A1
(en)
|
2010-11-30 |
2012-06-07 |
Genentech, Inc. |
Low affinity blood brain barrier receptor antibodies and uses therefor
|
|
CN103534272B
(zh)
|
2011-05-09 |
2016-05-11 |
株式会社英仙蛋白质科学 |
能够特异性识别转铁蛋白受体的抗体
|
|
TWI450727B
(zh)
|
2011-12-29 |
2014-09-01 |
財團法人工業技術研究院 |
抗人類輸鐵蛋白受體的單域抗體與其應用
|
|
US20130177579A1
(en)
|
2012-01-06 |
2013-07-11 |
Bioalliance C.V. |
Anti-transferrin receptor antibodies and methods using same
|
|
RU2711552C2
(ru)
|
2012-08-29 |
2020-01-17 |
Ф. Хоффманн-Ля Рош Аг |
Шаттл для гематоэнцефалического барьера
|
|
CA2893794C
(en)
|
2012-11-08 |
2021-11-09 |
University Of Miyazaki |
Antibody capable of specifically recognizing transferrin receptor
|
|
WO2014144060A1
(en)
|
2013-03-15 |
2014-09-18 |
Alper Biotech, Llc |
Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof
|
|
EA038367B1
(ru)
|
2013-05-20 |
2021-08-16 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА ТРАНСФЕРРИНА (TfR) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
|
|
US9499628B2
(en)
|
2013-06-14 |
2016-11-22 |
Children's Hospital Medical Center |
Method of boosting the immune response in neonates
|
|
EP3450557A1
(en)
|
2013-12-25 |
2019-03-06 |
JCR Pharmaceuticals Co., Ltd. |
Novel anti-transferrin receptor antibody that passes through blood-brain barrier
|
|
JP6557664B2
(ja)
|
2014-01-06 |
2019-08-07 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
一価の血液脳関門シャトルモジュール
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
IL310251A
(en)
|
2015-05-04 |
2024-03-01 |
Cytomx Therapeutics Inc |
Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof
|
|
CR20210429A
(es)
|
2015-06-24 |
2021-09-24 |
Hoffmann La Roche |
ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
|
|
KR20250073514A
(ko)
|
2015-06-24 |
2025-05-27 |
제이씨알 파마 가부시키가이샤 |
혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체
|
|
EP3325509B1
(en)
|
2015-07-22 |
2020-12-16 |
Inatherys |
Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
|
|
TWI819458B
(zh)
|
2015-10-02 |
2023-10-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
US20190240346A1
(en)
|
2016-06-20 |
2019-08-08 |
Genahead Bio, Inc. |
Antibody-drug conjugate
|
|
US20190375819A1
(en)
|
2016-10-29 |
2019-12-12 |
Rhode Island Hospital |
Glycosylated transferrin receptor 1 tumor antigen
|
|
NZ752703A
(en)
|
2016-12-26 |
2022-09-30 |
Japan Chem Res |
Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
|
|
CN110506054A
(zh)
|
2017-02-17 |
2019-11-26 |
戴纳立制药公司 |
经工程改造的多肽
|
|
US10457717B2
(en)
|
2017-02-17 |
2019-10-29 |
Denali Therapeutics Inc. |
Engineered polypeptides
|
|
HUE063021T2
(hu)
|
2017-08-10 |
2023-12-28 |
Denali Therapeutics Inc |
Mesterségesen elõállított transzferrin receptor-kötõ polipeptidek
|
|
CN118638788A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
SG11202006433PA
(en)
|
2018-02-05 |
2020-08-28 |
Jcr Pharmaceuticals Co Ltd |
Method for delivering drug to muscle
|
|
US20220378934A1
(en)
|
2018-08-02 |
2022-12-01 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
CA3108287A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
MX2021001282A
(es)
|
2018-08-02 |
2021-07-15 |
Dyne Therapeutics Inc |
Complejos dirigidos al músculo y sus usos.
|
|
JP7611825B2
(ja)
|
2018-08-02 |
2025-01-10 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
|
|
EA202190418A1
(ru)
|
2018-08-02 |
2021-06-23 |
Дайн Терапьютикс, Инк. |
Мышечно-специфические комлексы и их применение в лечении прогрессирующей оссифицирующей фибродисплазии
|
|
EP3829594A4
(en)
|
2018-08-02 |
2022-05-11 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
|
|
US20210322562A1
(en)
|
2018-08-02 |
2021-10-21 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating centronuclear myopathy
|
|
CA3108285A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
US20220193250A1
(en)
|
2018-08-02 |
2022-06-23 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US20210308274A1
(en)
|
2018-08-02 |
2021-10-07 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating friedreich's ataxia
|
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
|
WO2021076856A1
(en)
|
2019-10-18 |
2021-04-22 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CA3163608A1
(en)
|
2020-01-10 |
2021-07-15 |
Romesh R. Subramanian |
Muscle-targeting complexes and uses thereof
|
|
IL294479A
(en)
|
2020-01-10 |
2022-09-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and their uses for the treatment of myotonic dystrophy
|
|
US12624120B2
(en)
*
|
2020-01-31 |
2026-05-12 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (TfR) antibody and uses thereof
|
|
WO2022020105A1
(en)
|
2020-07-23 |
2022-01-27 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
CA3202832A1
(en)
|
2020-12-31 |
2022-07-07 |
Romesh R. Subramanian |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|